Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine

Wang, Nanxi; Yuan, Zhe; Niu, Wei; Li, Qingsheng; Guo, Jiantao

doi:10.1002/jctb.5174

Cited by 5 publications

(2 citation statements)

References 77 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although traditional live-attenuated vaccines (LAVs) are potent, the potential pathogenic consequences have aroused safety concerns [ 126 ]. Genetic code expansion strategy was first coupled with intact and infectious virus engineering using hepatitis D virus (HDV) as a model system [ 127 ].…”

Section: Therapeutic Vaccinesmentioning

confidence: 99%

Therapeutic applications of genetic code expansion

Huang

Liu

2018

Synthetic and Systems Biotechnology

View full text Add to dashboard Cite

In nature, a limited, conservative set of amino acids are utilized to synthesize proteins. Genetic code expansion technique reassigns codons and incorporates noncanonical amino acids (ncAAs) through orthogonal aminoacyl-tRNA synthetase (aaRS)/tRNA pairs. The past decade has witnessed the rapid growth in diversity and scope for therapeutic applications of this technology. Here, we provided an update on the recent progress using genetic code expansion in the following areas: antibody-drug conjugates (ADCs), bispecific antibodies (BsAb), immunotherapies, long-lasting protein therapeutics, biosynthesized peptides, engineered viruses and cells, as well as other therapeutic related applications, where the technique was used to elucidate the mechanisms of biotherapeutics and drug targets.

show abstract

Section: Therapeutic Vaccinesmentioning

confidence: 99%

Therapeutic applications of genetic code expansion

Huang

Liu

2018

Synthetic and Systems Biotechnology

View full text Add to dashboard Cite

show abstract

“…目前最常用的是失活或减毒的疫苗, 但是完全失活或减毒的疫苗往往会存在产率或是效力降低的问题 [83] . 最近基因密码子扩展技术也被用来制造ncAAs依赖的基因改造生物 (genetically modified organism, GMO [84,85] . 由于NP蛋白在流感病毒感染的过程中发挥着重要作用 [86,87] , 因此Zhou课题组 [84] [88] .…”

Section: 流感、埃博拉、Aids等流行病严重危害着人类的健康随着免疫学的进步和发展人们逐渐尝试用免unclassified

Therapeutic applications of genetic code expansion

Huang¹,

Wang²,

Hu³

et al. 2018

Sci. Sin.-Chim

View full text Add to dashboard Cite

Aterm Pregnancy Woman with Human Immunodeficiency Virus Infection and Antiretroviral Therapy as Risk Factor of High Caspase-3 Expression in Placenta

Prasetyo

Putra

Suwardewa

et al. 2022

EJMED

View full text Add to dashboard Cite

Aim: To determine whether term pregnant women with human immunodeficiency virus infection who received antiretroviral therapy have a high Caspase-3 expression in the placenta. Methods: This cross-sectional analytical study was conducted at Sanglah General Hospital, Denpasar, and affiliated hospitals. Subjects were termed pregnant women with HIV (+) who received a minimum of six months of antiretroviral therapy as a risk group and pregnant women with HIV (-) as a non-risk group. Caspase-3 expression was assessed by immunohistochemical examination of placental tissue. The cut-off value for caspase-3 levels was determined by constructing a receiver operating characteristics (ROC) curve. The difference in proportion was assessed by the chi-square test, and the prevalence ratio (PR) was reported. The significance of this study was p<0.05. Results: Each 20 pregnant women were included in the risk and no-risk groups. There was no difference in age, gestational age, parity, and body mass index (BMI) between the two groups. The mean expression of caspase-3 was significantly higher HIV (+) group than in the HIV (-) group (162.62 vs. 105.83; p = 0.000). The selected cut-off value of Caspase-3 was 127.05, with a sensitivity of 75% and a specificity of 75%. After classification, a significantly higher proportion of Caspase-3 expression was found in the HIV (+) group than in the HIV (-) group (75% vs. 25%; p=0.002). Pregnant women with HIV (+) and receiving antiretroviral therapy for a minimum of six months had a three times higher chance of having a high Caspase-3 prevalence than pregnant women who were not (RP=3.0; 95% CI = 1.348 – 6.678). Conclusion: Pregnant women with HIV infection who received antiretroviral therapy have a high Caspase-3 expression in the placenta.

show abstract

Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine

Cited by 5 publications

References 77 publications

Therapeutic applications of genetic code expansion

Therapeutic applications of genetic code expansion

Therapeutic applications of genetic code expansion

Aterm Pregnancy Woman with Human Immunodeficiency Virus Infection and Antiretroviral Therapy as Risk Factor of High Caspase-3 Expression in Placenta

Contact Info

Product

Resources

About